Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Albiges, Laurence; Powles, Tom; Staehlerr, Michael; Bensalan, Karim; Giles, Rachel H.; Horag, Milan; Kuczyk, Markus A.; Lam, Thomas B.; Ljungberg, Brje; Marconi, Lorenzo; Merseburger, Axel S.; Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed; Fernndez-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana and Bex, Axel (2019): Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. In: European Urology, Vol. 76, No. 2: pp. 151-156

Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naive). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 0302-2838
• Language: English